Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Long Term DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abivax (ABVX) Cash & Equivalents: 2021-2024

Historic Cash & Equivalents for Abivax (ABVX) over the last 4 years, with Dec 2024 value amounting to $154.1 million.

  • Abivax's Cash & Equivalents fell 71.18% to $69.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was $69.0 million, marking a year-over-year decrease of 71.18%. This contributed to the annual value of $154.1 million for FY2024, which is 43.15% down from last year.
  • Latest data reveals that Abivax reported Cash & Equivalents of $154.1 million as of FY2024, which was down 43.15% from $271.1 million recorded in FY2023.
  • Over the past 5 years, Abivax's Cash & Equivalents peaked at $271.1 million during FY2023, and registered a low of $28.4 million during FY2022.
  • For the 3-year period, Abivax's Cash & Equivalents averaged around $151.2 million, with its median value being $154.1 million (2024).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first slumped by 60.46% in 2022, then spiked by 854.35% in 2023.
  • Yearly analysis of 4 years shows Abivax's Cash & Equivalents stood at $71.8 million in 2021, then tumbled by 60.46% to $28.4 million in 2022, then soared by 854.35% to $271.1 million in 2023, then crashed by 43.15% to $154.1 million in 2024.